Wedbush analyst Laura Chico maintained a Hold rating on Vera Therapeutics (VERA – Research Report) today and set a price target of $21.00. The company’s shares closed yesterday at $25.31.
Chico covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Ardelyx, and Apellis Pharmaceuticals. According to TipRanks, Chico has an average return of 1.9% and a 49.03% success rate on recommended stocks.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Vera Therapeutics with a $27.14 average price target.
See Insiders’ Hot Stocks on TipRanks >>
VERA market cap is currently $1.12B and has a P/E ratio of -8.81.
Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of VERA in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vera Therapeutics (VERA) Company Description:
Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company’s lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.
Read More on VERA:
- Vera Therapeutics Reports Positive Phase 2b ORIGIN Trial Results
- Vera Therapeutics Announces Promising 72-Week Trial Results
- Vera Therapeutics to host research and development day
- Vera Therapeutics’ atacicept shows positive Phase 2b data in IgA nephropathy
- Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy
